Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorolanib - Equinox Sciences/EyePoint Pharmaceuticals

Next Previous
X
Search
Drug Profile

Vorolanib - Equinox Sciences/EyePoint Pharmaceuticals

Alternative Names: DURAVYU; DURAVYUT; EYP 1901; Vorolanib - Xcovery Holdings

Latest Information Update: 12 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tyrogenex
  • Developer EyePoint Pharmaceuticals
  • Class Amides; Antineoplastics; Eye disorder therapies; Fluorinated hydrocarbons; Indoles; Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic macular oedema; Diabetic retinopathy
  • Preclinical Choroidal neovascularisation
  • No development reported Retinal vein occlusion

Most Recent Events

  • 12 Feb 2025 Updated efficacy and adverse event data from the phase III trial in Diabetic macular oedema released by EyePoint Pharmaceuticals
  • 05 Feb 2025 EyePoint announces intention to meet with the US FDA for initiation of a phase III clinical trial in second quarter of 2025
  • 05 Feb 2025 EyePoint plans a phase III non-inferiority pivotal program for Diabetic macular oedema by the end of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top